Neurovation Labs is a biotech company aiming to revolutionize the way psychiatric disorders are diagnosed and treated, with an initial focus on Post-traumatic Stress Disorder (PTSD).
Neurovation Labs’ first product is a brain penetrant, patent-pending diagnostic tracer for use in PET scanning and other nuclear imaging techniques. The tracer, currently under preclinical optimization, is designed to target the first putative PTSD biomarker, discovered by our co-founders Drs. Jennifer Perusini and Michael Fanselow. Neurovation Labs’ second product is a non-invasive treatment for PTSD, currently in preclinical development. The treatment is designed to inhibit the same PTSD biomarker and can be used as a companion to Neurovation Labs’ PTSD diagnostic.
PTSD is a serious mental health condition characterized by debilitating symptoms that interfere with daily life function. The current ineffective diagnostic and treatment options overwhelm healthcare services and cause a huge economic burden. Neurovation Labs is leveraging its biomarker discovery to develop two products that take the guesswork out of diagnosing and treating PTSD.